Recombinant Peptides Ce1 and Ce4 from the Venom of Scorpion Centruroides elegans and Their Interactions with Hybrid Channels KcsA-Kv1.x (x = 1, 3, 6)
暂无分享,去创建一个
[1] D. Dolgikh,et al. GFP–Margatoxin, a Genetically Encoded Fluorescent Ligand to Probe Affinity of Kv1.3 Channel Blockers , 2022, International journal of molecular sciences.
[2] Fernando Castro-Herrera,et al. Pharmacological blockade of KV1.3 channel as a promising treatment in autoimmune diseases , 2022, Journal of translational autoimmunity.
[3] A. Todd,et al. Studying Independent Kcna6 Knock-out Mice Reveals Toxicity of Exogenous LacZ to Central Nociceptor Terminals and Differential Effects of Kv1.6 on Acute and Neuropathic Pain Sensation , 2021, The Journal of Neuroscience.
[4] L. Pardo,et al. Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges , 2021, Medicinal research reviews.
[5] H. Wulff,et al. Kv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling , 2020, Channels.
[6] A. Liantonio,et al. Kv1.1 Channelopathies: Pathophysiological Mechanisms and Therapeutic Approaches , 2020, International journal of molecular sciences.
[7] L. Chow,et al. The versatile Kv channels in the nervous system: actions beyond action potentials , 2020, Cellular and Molecular Life Sciences.
[8] A. Feofanov,et al. Fluorescent Ligands of Kv1 Channels on the Basis of Hongotoxin: Atto488-Hongotoxin , 2019, Microscopy and Microanalysis.
[9] R. Norton,et al. Peptide therapeutics from venom: Current status and potential. , 2017, Bioorganic & medicinal chemistry.
[10] E. Muñoz-Elías,et al. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial , 2017, PloS one.
[11] Yuliya V. Korolkova,et al. Complexes of Peptide Blockers with Kv1.6 Pore Domain: Molecular Modeling and Studies with KcsA-Kv1.6 Channel , 2017, Journal of Neuroimmune Pharmacology.
[12] M. Kirpichnikov,et al. Straightforward approach to produce recombinant scorpion toxins-Pore blockers of potassium channels. , 2017, Journal of biotechnology.
[13] E. Grishin,et al. Fluorescent protein-scorpion toxin chimera is a convenient molecular tool for studies of potassium channels , 2016, Scientific Reports.
[14] E. Grishin,et al. Diversity of Potassium Channel Ligands: Focus on Scorpion Toxins , 2015, Biochemistry (Moscow).
[15] Z. Varga,et al. Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels. , 2014, Toxicon : official journal of the International Society on Toxinology.
[16] Shin-Ho Chung,et al. Binding Modes of Two Scorpion Toxins to the Voltage-Gated Potassium Channel Kv1.3 Revealed from Molecular Dynamics , 2014, Toxins.
[17] E. Campbell,et al. Structure of a pore-blocking toxin in complex with a eukaryotic voltage-dependent K+ channel , 2013, eLife.
[18] E. Grishin,et al. Fluorescent system based on bacterial expression of hybrid KcsA channels designed for Kv1.3 ligand screening and study , 2013, Analytical and Bioanalytical Chemistry.
[19] R. Latorre,et al. K(+) channels: function-structural overview. , 2012, Comprehensive Physiology.
[20] Y. Jan,et al. Voltage‐gated potassium channels and the diversity of electrical signalling , 2012, The Journal of physiology.
[21] Heike Wulff,et al. Voltage-gated potassium channels as therapeutic targets , 2009, Nature Reviews Drug Discovery.
[22] A. Morielli,et al. Kv1.3 channels in postganglionic sympathetic neurons: expression, function, and modulation. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.
[23] P. Calabresi,et al. Characterization of the Functional Properties of the Voltage-Gated Potassium Channel Kv1.3 in Human CD4+ T Lymphocytes1 , 2007, The Journal of Immunology.
[24] H. Gruppen,et al. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. , 2007, Journal of agricultural and food chemistry.
[25] S. Confort-Gouny,et al. Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy , 2006, Annals of neurology.
[26] Juan A. Fernández,et al. Novel alpha-KTx peptides from the venom of the scorpion Centruroides elegans selectively blockade Kv1.3 over IKCa1 K+ channels of T cells. , 2005, Toxicon : official journal of the International Society on Toxinology.
[27] R. C. Rodríguez de la Vega,et al. Novel interactions between K+ channels and scorpion toxins. , 2003, Trends in pharmacological sciences.
[28] K. Chandy,et al. Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. , 2001, Toxicon : official journal of the International Society on Toxinology.
[29] O. Pongs,et al. Generating a High Affinity Scorpion Toxin Receptor in KcsA-Kv1.3 Chimeric Potassium Channels* , 2000, The Journal of Biological Chemistry.
[30] A. Koschak,et al. Subunit Composition of Brain Voltage-gated Potassium Channels Determined by Hongotoxin-1, a Novel Peptide Derived fromCentruroides limbatus Venom* , 1998, The Journal of Biological Chemistry.
[31] R. MacKinnon,et al. Purification and characterization of three inhibitors of voltage-dependent K+ channels from Leiurus quinquestriatus var. hebraeus venom. , 1994, Biochemistry.
[32] G A Gutman,et al. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. , 1994, Molecular pharmacology.
[33] E. Grishin,et al. Potassium Channel Blockers in Mesobuthus eupeus 1 Variability of Potassium Channel Blockers in Mesobuthus eupeus Scorpion Venom with Focus on Kv1.1: an Integrated Transcriptomic and Proteomic Study* , 2015 .
[34] J. Tropea,et al. Expression and purification of soluble His(6)-tagged TEV protease. , 2009, Methods in molecular biology.
[35] K. Giangiacomo,et al. Molecular basis of alpha-KTx specificity. , 2004, Toxicon : official journal of the International Society on Toxinology.